Protagonist Therapeutics, Inc. PTGX 深 滬
已收盤 12-19 16:00:00 美东时间
86.05
+0.260
+0.30%
華盛通- 最 高87.73
- 今 開86.58
- 成交量 173.65万股
- 最 低 84.81
- 昨 收 85.79
- 總市值 53.53亿
- 52周最高 96.54
- 市盈率 靜 20.35
- 換手率 2.79%
- 52周最低 33.70
- 委 比 38.64%
- 總股本 6221.13万
- 歷史最高 96.54
- 量 比 1.41
- 振 幅 3.40%
- 歷史最低 4.47
- 每 手 1
- 風險率 15.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $108
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $88 to $108.
12-18 01:54
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Reported Saturday, Protagonist Therapeutics And Takeda Highlight VERIFY And THRIVE Data Showing Long-Term Hematocrit Control And Reduced Therapeutic Phlebotomy In PV At ASH 2025
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive
12-08 17:05
Protagenic Therapeutics receives Nasdaq non-compliance letter
Protagenic Therapeutics (PTIX) has received a notification letter from Nasdaq indicating its non-compliance with the exchange’s listing rules, namely the minimum stockholders' equity requirement and t...
11-27 19:39
Comerica investor HoldCo pushes back at sale to Fifth Third
Comerica (CMA) investor HoldCo Asset Management wants the bank to release additional details on its planned sale to Fifth Third Bancorp (FITB) as it calls the sales process "flawed." While HoldCo push...
11-17 23:11
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Citizens Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $102
Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $69 to $102.
11-07 22:13
